Entero Therapeutics (Nasdaq: ENTO)

Entero Therapeutics, Inc., is a biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases

[Entero Therapeutics (Nasdaq: ENTO) @enterothera]

Today, @enterothera announced a business update relating to the recent progress of our #latiglutenase program.

Read more here: https://t.co/8dezb5KIyf
$ENTO

[Entero Therapeutics (Nasdaq: ENTO) @enterothera]

We’re delighted to share our recent publication in the prestigious @AmerGastroAssn journal, Clinical Gastroenterology and Hepatology, that sheds light on a new, quantitative approach to diagnosing and measuring #CeliacDisease severity.

Learn more: https://t.co/ghq7dpLLmA

[Entero Therapeutics (Nasdaq: ENTO) @enterothera]

#CeliacDiseaseResearch tackles disease management with multiple means.

Our enzymatic approach, #latiglutenase, breaks down gluten into harmless fragments, aiding gluten digestion for all people living with #CeliacDisease.

Learn more about approaches: https://t.co/3AQ7ZJ9fOy

[Entero Therapeutics (Nasdaq: ENTO) @enterothera]

.@enterothera is proud to have partnered with @CeliacJourneyUS to support #CeliacDiseaseResearch and clear gluten labeling on food at the @Nasdaq Tower.

Join us in supporting young advocates like Jax Bari as they champion these crucial causes.

#CeliacDisease #advocacy

[Entero Therapeutics (Nasdaq: ENTO) @enterothera]

Our Phase 3-ready asset #latiglutenase acts like Lactaid for gluten--breaking down gluten into irrelevant fragments and reducing the severity and frequency of symptoms in celiac disease patients.

Learn more: https://t.co/Kq4rVFjikE

[Entero Therapeutics (Nasdaq: ENTO) @enterothera]

.@enterothera is pleased to announce an upcoming presentation on #CeliacResearch at the 20th International Celiac Disease Symposium, September 5-7 in Sheffield, U.K.

More details here: https://t.co/FZUPpRicKt

#CeliacDisease

[Entero Therapeutics (Nasdaq: ENTO) @enterothera]

.@enterotx wishes you and your loved ones a happy and relaxing holiday!

[Entero Therapeutics (Nasdaq: ENTO) @enterothera]

We’re happy to announce that our research has been featured in @BeyondCeliac’s Research News article. Read about how greater gluten challenges may be required for accurate celiac disease testing.

Check it out: https://t.co/qgCSu4mPcV

$ENTO #CeliacResearch

[Entero Therapeutics (Nasdaq: ENTO) @enterothera]

We’re pleased to announce our groundbreaking publication in @AmerGastroAssn’s Clinical Gastroenterology and Hepatology.

Our #CeliacResearch introduces a quantitative approach to diagnosing and assessing disease severity of #CeliacDisease.

Learn more: https://t.co/ghq7dpLLmA

[Entero Therapeutics (Nasdaq: ENTO) @enterothera]

#ICYMI: @FiercePharma recently covered our strategic rebranding, rejuvenated company mission, and the Phase 3-ready asset latiglutenase.

Read about our transformation here: https://t.co/88BMXpDrfw

#CeliacDisease

[Entero Therapeutics (Nasdaq: ENTO) @enterothera]

Last week, @EnteroThera participated in the 2024 #BIO International Convention.

It was a great opportunity for networking and learning about the hottest trends in the field.

Looking forward to next year!

#BIO2024 #BIOInternational #BioTech

[Entero Therapeutics (Nasdaq: ENTO) @enterothera]

Our very own James Sapirstein, CEO of @enterothera and board member of #BIO recently shared his thoughts on the #BiosecureAct with @endpts.

Check it out:
https://t.co/7GIUmGhDlu

#BIO2024 #BIOInternational

[Entero Therapeutics (Nasdaq: ENTO) @enterothera]

Yesterday, @enterothera presented at the 2024 @BIOConvention in San Diego.

Thanks for having us and we look forward to attending again next year!

#BIO2024 #BIOInternational #BioTech

[Entero Therapeutics (Nasdaq: ENTO) @enterothera]

.@enterothera would like to thank @CeliacDotOrg, @BeyondCeliac, @SSCDCeliac, and The International Society for the Study of Celiac Disease for the opportunity to participate in #DDW2024.

We’re glad to work side-by-side in the fight against #CeliacDisease. #DigestiveDiseaseWeek

[Entero Therapeutics (Nasdaq: ENTO) @enterothera]

.@EnteroThera will present at the 2024 @BIOConvention in San Diego, Tuesday, June 4 at 10:30 a.m. PDT.

Meet us there: https://t.co/ww1IW6Dp0M

#BIO2024

[Entero Therapeutics (Nasdaq: ENTO) @enterothera]

Entero Therapeutics is pleased to announce two poster presentations on #CeliacDiseaseResearch at the 2024 @DDWMeeting Conference.

Check out details of our presentations here: https://t.co/QeWqcbLUC3

#DDW2024 #DigestiveDiseaseWeek

[Entero Therapeutics (Nasdaq: ENTO) @enterothera]

.@enterothera supports @CeliacJourneyUS taking the stage to promote #CeliacDiseaseResearch and #CeliacDiseaseAwarenessMonth!👏

Tune in to the @TODAYshow as we celebrate Jax Bari shedding light on the importance of clear gluten labeling on food packages:
https://t.co/eIBsOtz1Tc

[Entero Therapeutics (Nasdaq: ENTO) @enterothera]

Today we proudly partnered with @CeliacJourneyUS to #ShineALightOnCeliac at the @Nasdaq Tower in honor of #CeliacDiseaseAwarenessMonth and #InternationalCeliacDay.

#CeliacDisease #CeliacDiseaseResearch #Advocacy

[Entero Therapeutics (Nasdaq: ENTO) @enterothera]

Today, we announced our new corporate name: Entero Therapeutics, underscoring our commitment to addressing unmet needs in #GastrointestinalDisease that include #CeliacDisease.

Learn more here: https://t.co/02tVwwQhOe

#CeliacDiseaseResearch

[Entero Therapeutics (Nasdaq: ENTO) @enterothera]

In honor of #CeliacDiseaseAwarenessMonth, First Wave BioPharma and @CeliacJourneyUS announce an awareness digital display on the @Nasdaq Tower on May 16 at 4:25 p.m. ET.

Join First Wave and Celiac Journey as they #ShineALightOnCeliac: https://t.co/ewYW7hqGa9

#CeliacDisease